Efficacy and safety of low dose,weight-based subcutaneous enoxaparin protocol in recurrent arteriovenous access thrombosis

Abstract

Background:

This study aims to evaluate the safety and efficacy of a short-term, low dose, weight-based subcutaneous enoxaparin protocol (SEP) in maintaining the patency of arteriovenous (AV) access with recurrent thrombosis.

Methods:

Prospective follow-up of 25 patients who presented to a tertiary institution with recurrent AV access thrombosis and treated with anticoagulation according to SEP following successful thrombectomy. Patency and safety outcomes of SEP were studied.

Results:

The participants were 66.4 ± 10.2 years old and predominantly male (60%) and of Chinese ethnicity (72%). The AV accesses had a median age of 1.4 (0.6, 5.6) years with 60% being non-autogenous arteriovenous access while 40% were autogenous arteriovenous access. Thrombolytic agents (urokinase (72%) or alteplase (28%)) were used in all procedures while adjunct thrombectomy device was used in only four procedures. The mean dose of enoxaparin was 36.0 ± 8.2 mg or 0.64 ± 0.1 mg/kg/day for a mean duration 30.0 days (Interquartile range: 27.5, 31.0). One patient developed minor bleeding episode. Kaplan-Meier analysis demonstrated that the mean thrombosis-free survival pre- versus post-SEP adoption was 27.3 (95% CI 17.9–36.7) versus 183.5 (95% CI 100.1–266.9) days (p < 0.001). After adjusting for the type of thrombolytic agent, use of adjunct thrombectomy device, cutting balloon, drug-coated balloon, and stent graft, SEP remained a significant factor associated with longer thrombosis-free patency (HR 0.166: 95% CI 0.070–0.392, p < 0.001).

Discussion:

SEP appears to be a feasible and safe thromboprophylaxis method to improve thrombosis-free patency for AV access with recurrent thrombosis.

Keywords

Recurrent arteriovenous access thrombosis enoxaparin lower molecular weight heparin access patency thrombectomy and thrombolysis dialysis access thromboprophylaxis AV fistula prosthetic grafts

Get full access to this article

View all access options for this article.

References

Thamer

Lee

Wasse

, et al. Medicare costs associated with arteriovenous fistulas among US hemodialysis patients. Am J Kidney Dis 2018; 72(1): 10–18.

Kaufman

O’Connor

Zhang

, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003; 14(9): 2313–2321.

Crowther

Clase

Margetts

, et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol 2002; 13(9): 2331–2337.

Dixon

Beck

Vazquez

, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 2009; 360(21): 2191–2201.

Chang

T-I

Chen

C-H

Hsieh

H-L

, et al. Effects of cardiovascular medications on primary patency of hemodialysis arteriovenous fistula. Sci Rep 2020; 10(1): 12135–12141.

Tan

Pang

Teh

, et al. Outcomes of endovascular salvage of clotted arteriovenous access and predictors of patency after thrombectomy. J Vasc Surg Cases 2020; 71(4): 1333–1339.

Tan

Pang

Teh

, et al. Comparison of alteplase and urokinase for pharmacomechanical thrombolysis of clotted hemodialysis access. J Vasc Access 2019; 20(5): 501–506.

Sidawy

Gray

Besarab

, et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg 2002; 35(3): 603–610.

Schulman

Kearon

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3(4): 692–694.

10.

Smits

JHM

van der Linden

Blankestijn

, et al. Coagulation and haemodialysis access thrombosis. Turk Nephrol Dial Transplant 2000; 15(11): 1755–1760.

11.

Lajvardi

Trerotola

Strandberg

, et al. Evaluation of venous injury caused by a percutaneous mechanical thrombolytic device. Cardiovasc Intervent Radiol 1995; 18(3): 172–178.

12.

Hughes

Szeki

Nash

, et al. Anticoagulation in chronic kidney disease patients—the practical aspects. Clin Kidney J 2014; 7(5): 442–449.

13.

Chan

Thadhani

Maddux

FW.

No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease. Kidney Int 2013; 84(3): 555–561.

14.

Green

Tellor

Buckallew

AR.

Safety and efficacy of enoxaparin compared with unfractionated heparin for venous thromboembolism prophylaxis in hemodialysis patients. Hosp Pharm 2017; 52(9): 623–627.

15.

Tan

Pang

Tng

ARK

, et al. Effect of short-term low molecular weight heparin on patency following successful salvage of arteriovenous access with recurrent thrombosis. Nephrology (Carlton) 2021; 26(4): 350–357.